MAKING THE CONNECTION: Between Patients and Providers
– DEEP DIVE SERIES –
An Integrative Approach to the Treatment of Type 1 and Type 2 Diabetes
An Enduring CME Activity – 3.0 CEUs
**Once registered you will receive a confirmation email with a quick access link to the activity**
LEARN ABOUT CUTTING-EDGE DIABETES TREATMENTS AND BREAKTHROUGH CLINICAL RESEARCH THAT HAVE CHANGED THE WAY WE TREAT OUR PATIENTS WITH DIABETES!
There have been game-changing developments treating patients with type 1 and type 2 diabetes and we’re taking a deep dive into topics that should be every practitioner’s standard of care. From effectively translating continuous glucose monitor (CGM) data, to finding medications that positively impact the cardiorenal system, to learning about developments in the slowing and prevention of type 1, this is the info you need to know to efficiently and effectively treat your patients with diabetes.
**Once registered you will receive a confirmation email with a quick access link to the activity**
“Overall, superb presentation. Enjoyed the medication updates. Presenters are easy to listen to, and are definitely experts that present in a friendly manner.”
PROGRAM TOPICS
We focus on three distinct areas of the most cutting-edge diabetes management strategies:
• Preventing, Halting, and Reversing Type 1 Diabetes: Update in T1D research and potential novel therapies
• Efficient and Compressive type 2 diabetes management: glucose, renal, and cardiovascular health
• Rapid CGM interpretation for efficient and effective clinical visits
LEARNING OBJECTIVES
Upon completion of these activities, participants should be able to:
1. Identify the different pathophysiologic defects associated with type 2 diabetes and how all the pharmacologic agents (oral and injectable) address these specific abnormalities including patients with very poor glycemic control and elevated insulin requirements.
2. Discuss the recently published cardiovascular-renal outcome trials on oral (SGLT2 inhibitors) and injectable type 2 medications (GLP1-RAS).
3. Evaluate the use of SGLT-2 and GLP-1 RA in patients who have cardiovascular risks factors and are at risk or have a history of atherosclerotic cardiovascular disease (ASCVD).
4. Design a treatment plan for multiple daily injection regimens and insulin pump therapy including hybrid closed loop systems.
5. Select effective therapeutic adjustments based on CGM trending or rate of change arrows, time in range, and standard deviation.
6. Recognize the physical and emotional barriers that prevent patients with diabetes from being persistent and adherent to their therapeutic regimen(s).
7. Employ innovative and dynamic strategies for communication with patients to strengthen provider-patient relations.
TARGET AUDIENCE
This course is designed for diabetes healthcare providers including endocrinologists, primary care physicians, nurse practitioners, physician assistants, nurses, certified diabetes educators, pharmacists, registered dietitians, and other healthcare providers wanting to expand their knowledge of diabetes management.
**Once registered you will receive a confirmation email with a quick access link to the activity**
SPEAKERS & FACULTY
*extra-relatable faculty (they're living with type 1)
*STEVEN V. EDELMAN, MD
Founder & Director, TCOYD; Endocrinologist, Clinical Professor of Medicine, University of California, San Diego (UCSD) School of Medicine; Director, Diabetes Care Clinic, VA Medical Center San Diego
Dr. Edelman is a professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California, San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego. Dr. Edelman, who has type 1 diabetes himself, has written more than 200 articles, five books, and has won numerous awards for teaching and humanitarianism. He has been chosen by the medical students at UCSD as the ‘teacher of the year’ numerous times. Among his many honors, Dr. Edelman has received the ‘Diabetes Educator Of The Year’ award by the American Diabetes Association, the ‘Distinction in Endocrinology’ award by the American Association of Clinical Endocrinologists, and named ‘Top 1% of U.S. Endocrinologists’ by US News and World Report.
*JEREMY PETTUS, MD
Type 1 Track & Professional Education Director, Endocrinologist, Associate Professor of Medicine, UCSD School of Medicine
Dr. Jeremy Pettus was diagnosed with type 1 diabetes when he was 15 years old. Since that time he has dedicated his career to educating and treating others like himself. He is currently an Endocrinologist and Associate Professor of Medicine at the University of California, San Diego. There, he focuses primarily on clinical trials to develop and test new and innovative therapies for people living with diabetes. These include studies ranging from medications to reverse or slow the disease once it occurs, to islet cell transplantation strategies, to device studies such as artificial pancreas technology. As somebody who has the disease himself, sees patients with type 1, and is actively working on curing/treating the disease, we are honored to have him at TCOYD.
TRICIA SANTOS, MD
Type 2 Track Co-Director, Endocrinologist, Assistant Clinical Professor of Medicine, UCSD School of Medicine
Dr. Santos did her endocrinology training under Dr. Edelman who sparked a love for all things diabetes and always kept things both “educational & entertaining.” Now she is an Assistant Clinical Professor at UCSD where she wears many different hats. She has a special interest in caring for diabetic patients and helping them take a more active role in managing their diabetes. She directs the Diabetes & Endocrinology courses at the UCSD School of Medicine. She also teaches doctors in training and primary care physicians where she focuses on the importance of the doctor-patient relationship and involving the patient in medical decision making. Her love of teaching patients, students, and doctors has been recognized by several teaching awards. Her research focuses on investigating new and advanced therapies and technology for people with diabetes.
*AARON KOWALSKI, PhD
President & Chief Executive Officer, JDRF
As CEO of JDRF, a global leader in type 1 diabetes (T1D) research, Dr. Kowalski drives strategies to accelerate progress toward cures — and simultaneously advance breakthroughs that enable people with T1D to live longer, healthier lives.
Dr. Kowalski, an internationally recognized scientific expert in T1D research, brings his personal experience of living with T1D for over 35 years to his life’s work. He is a champion of the T1D community and a passionate advocate for federal research funding as well as for coverage, choice and affordability of T1D technology and treatments.
**Once registered you will receive a confirmation email with a quick access link to the activity**
This activity is jointly provided by Global Education Group and Taking Control Of Your Diabetes.
This activity is supported by an educational grant from Medtronic, Abbott Diabetes Care, Dexcom, Novo Nordisk, and Vertex.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Taking Control of Your Diabetes. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 3.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Global Education Group designates this continuing education activity for 3.0 contact hour(s) (0.30 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-22-109-H01-P)
This is a knowledge-based activity.
Dietitian Accreditation Statement
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012
*CDR learners may submit their program evaluation directly to the CDR
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and (name of other entity). Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 3.0 contact hour(s) (which includes 0.1 hour(s) of pharmacology).
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
| Steven V. Edelman, MD | Advisor: AstraZeneca, BrightSight, InPen, Lexicon, Lilly USA, LLC, MannKind Corporation, Merck, Sanofi-aventis U.S. Inc.
Consultant: Sensionics, Team Type 1 Speakers’ Bureau: AstraZeneca, Lilly USA, LLC, MannKind Corporation, Merck, Sanofi-aventis U.S. Inc. |
| Jeremy Pettus, MD | Consultant: Carmot, Diasome, Novo Nordisk, Sanofi
Speakers’ Bureau: MannKind, Sanofi |
| Tricia Santos, MD | Consultant: 9am Health |
| Aaron Kowalski, PhD | Nothing to disclose |
The planners and managers have the following relevant financial relationships with ineligible companies:
| Name of Planner or Manager | Reported Financial Relationship |
| Rhys Williams, MSN, FNP-C, RN | Nothing to disclose |
| Kristin Delisi, NP | Nothing to disclose |
| Amanda Turner MS, RDN, CSSD | Nothing to disclose |
| Lindsay Borvansky | Nothing to disclose |
| Andrea Funk | Nothing to disclose |
| Liddy Knight | Nothing to disclose |
| Ashley Cann | Nothing to disclose |
| Sarah Severance | Nothing to disclose |
Term Offering
This activity was released on 8/12/2022 and is valid for one year. Requests for credit must be made no later than 8/12/2023.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must register for the event, complete the accredited modules (4), and successfully complete the post test and evaluation.
APPLICATION PROCESS:
- Click on claim credit on the activity page after completing the full activity, or go to this web address:
- http://tcoyd.webedcafe.com/decision/2618/5/DD-Endure
- Click on the link representing your profession
- Fill out the complete credit application form and click “Continue to Post-test”
- Complete the post-test and click “Continue”
- Complete the evaluation form and click “Submit”
- Successful applicants will be able to download a certificate, and a copy of the certificate will also be emailed to you. (Pharmacists will receive instructions on the certificate.)
System Requirement
| PC 1.4 GHz Intel Pentium 4 or faster processor (or equivalent) Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit) 512 MB of RAM (1 GB recommended)Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google ChromeFor HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) |
MAC 1.83 GHz Intel Core Duo or faster processor 512 MB of RAM (1 GB recommended) MAC OS X 10.12, 10.13 and 10.14Mozilla Firefox, Apple Safari, Google ChromeFor HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above) |
Fee Information & Refund/Cancellation Policy
This is a complementary activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Taking Control of Your Diabetes do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
